Stay updated with breaking news from Prime Editing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- Collaboration combines Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy Pairs™ (SCIP™) platform -- -- Aim to reduce toxicity of conditioning regimens and introduce new therap...
CAMBRIDGE, Mass., May 17, 2023 -- Prime Medicine, Inc. , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that... | May 17, 2023
Prime Medicine has yet to test prime editing in humans, but the biotech company garnered enough investor interest to boost the size of its IPO, raising $175 million. Prime claims its technology has key advantages over other gene-editing technologies and the IPO cash will support a pipeline that currently spans 18 programs.
The pharma giant wants to repair genes with its own technology as a way to cure diseases, AstraZeneca's Steve Rees told Insider.